Submitter:	Megan Frost
On Behalf Of:	HB2387
Committee:	House Committee On Behavioral Health and Health Care
Measure, Appointment or Topic:	HB2387

Dear Chair Nosse, co-chairs Javadi and Nelson, and committee members.

I am writing in passionate support of HB2387, the Psilocybin Improvement Bill. My name is Megan Frost. I am a cancer surgeon, a public health expert, a prescriber for Death with Dignity, a graduate of the California Institute of Integral Studies Certificate in Psychedelic Therapy and Research, a board member for the service center Omnia Group, and a proud Oregonian since 2006.

I have seen exciting outcomes with psilocybin therapy for people suffering many kinds of trauma but near and dear to my heart and profession is the psychological benefits that I've seen help people navigate cancer journeys and the end of their lives. I have been humbled as a surgeon knowing that I cannot cure everyone's cancer and that even when cured our treatments and the fear of death and recurrence create their own traumas. Psilocybin therapy has helped many of my patients heal mentally, emotionally, and spiritually in light of difficult medical diagnoses and even impending death. As a prescriber for Death with Dignity, I often meet people who have come to terms with their death and found peace. If I could give that gift to everyone, it would be as honorable as it is to remove their cancer. Psilocybin has done that for many people.

I am have worked alongside many other doctors, nurses, and therapists that are passionate about serving their patients through their chosen profession AND know the benefits of psilocybin therapy that would also serve their patients. Under our current law, they are not able to use their licenses in their field while facilitating which is a great disservice to both the client and the provider as these healing processes are all intimately intertwined. HB2387 provides protections for these licensed providers to discuss psilocybin therapy with their patients without fear of losing their licenses. Clients also need to be fully informed of both they mental and physical healthcare risks and these providers are best able to do so. Without this, more adverse events will occur and clients will not have the proper education to make safe decisions.

HB2387 also establishes membership requirements for the Psilocybin Advisory Board. Any board should have members that hold expertise in said area to inform the board of recommendations for program improvements, concerns, etc. The bill supports that one licensed psilocybin facilitator, a service center operator, and a licensed behavioral professional have seats on the board making it much more robust.

Lastly HB2387, requires that psilocin be labeled on psilocybin products helping both client and facilitator understand the potency of the product they are using which makes the process significantly safer. As a doctor, I would never use a medication on a patient that I didn't fully understand it's potency as it would be both risky and then difficult to understand how effective the medication was.

I was ecstatically proud that Oregon began leading the country in its mental health care with Measure 109 and HB2387 will make it safer and more accessible. Thank you for your consideration and all of your hard work for our community.

Megan Frost MD, MPH Grants Pass 5039755396 Megan.marie.frost@gmail.com